Abstract: In gene expression frequency analysis, a vector primer to which each cDNA is ligated is formed by synthesizing the cDNA from each mRNA using by a vector primer having a poly(T) sequence; each cDNA sequence is converted to a tag on the vector primer; a concatemer is formed by ligating the obtained tags via a sequence that enables recognition of ends of the tags; and the nucleotide sequence of the concatemer is analyzed.

Abstract: A gene panel comprising genes each showing, in hepatic stellate cells, a varied expression level in a hepatic stellate cell activation state compared with a level in a normal state, comprising the steps of:

Abstract: A polypeptide having a production level specifically lowered in human diseased human livers. This polypeptide provides a novel diagnostic means for hepatitis by determining the production level of the polypeptide or an mRNA encoding the polypeptide in the liver.

Abstract: Each gene in a group comprising many genes is cloned into an expression vector so that its gene product should be expressed as a fusion protein with a protein emitting self-fluorescence to construct a gene expression library. The gene expression library is introduced into cells of two groups to express the fusion proteins in the cells, and only one cell group is stimulated by a drug or the like. Then, cells in which the fusion proteins are localized in the nuclei or their nuclei are isolated from cells of the two groups, respectively. By comparing these cells, genes coding for proteins that are transported into the nuclei specifically in response to a certain stimulus when the stimulus is applied to the cells are retrieved.

Abstract: The present invention relates to a modified physiologically active protein, modified physiologically active proteins produced by the process and pharmaceutical compositions containing the same.

Abstract: A connection box includes a wiring board. The box includes a control board connected to the wiring board. The control board including a control device and another device separated thereinto. Another device has generation heat greater than the control device.

Abstract: A connection box includes a wiring board. The box includes a control board connected to the wiring board. The control board including a control device and another device separated thereinto. Another device has generation heat greater than the control device.

Abstract: Heat-generating components, such as relays (14), are mounted on a board (13) via a relay block (15). Further, a conduction prevention section A is defined on the board (14) between a control component and the relays (14). Provided on an interior surface of an upper cover (11) constituting an electric junction box (10) are convection-of-air prevention walls (19) which come into contact with a mount inhibition area (B) within the conduction prevention section (A) on the board (13).

Abstract: A flow cell 2, a composite lens 15, and first to third detectors 16 to 18 are arranged in this sequence in the light pathway of light emitted from a laser light source 1. The composite lens 15 is configured by a convex lens 15a, and lens elements 15b and 15c. These lenses have different focal lengths. When the posture of the composite lens is correct, light impinging on the convex lens forms an image on the first detector. Therefore, the positioning of the composite lens is enabled. When particles in the flow cell are irradiated with laser light, forward scatter is produced. Forward small angle scatter having a small scattering angle impinges on the first lens element 15b to be collected thereby, and is then received by the second detector 17. Forward large angle scatter having a large scattering angle impinges on the second lens element 15c in the outermost periphery to be collected thereby, and is then received by the third detector 18 which is remotest from the composite lens.

Abstract: A flow cell 2, a composite lens 15, and first to third detectors 16 to 18 are arranged in this sequence in the light pathway of light emitted from a laser light source 1. The composite lens 15 is configured by a convex lens 15a, and lens elements 15b and 15c. These lenses have different focal lengths. When the posture of the composite lens is correct, light impinging on the convex lens forms an image on the first detector. Therefore, the positioning of the composite lens is enabled. When particles in the flow cell are irradiated with laser light, forward scatter is produced. Forward small angle scatter having a small scattering angle impinges on the first lens element 15b to be collected thereby, and is then received by the second detector 17. Forward large angle scatter having a large scattering angle impinges on the second lens element 15c in the outermost periphery to be collected thereby, and is then received by the third detector 18 which is remotest from the composite lens.

Abstract: A flow cell 2, a composite lens 15, and first to third detectors 16 to 18 are arranged in this sequence in the light pathway of light emitted from a laser light source 1. The composite lens 15 is configured by a convex lens 15a, and lens elements 15b and 15c. These lenses have different focal lengths. When the posture of the composite lens is correct, light impinging on the convex lens forms an image on the first detector. Therefore, the positioning of the composite lens is enabled. When particles in the flow cell are irradiated with laser light, forward scatter is produced. Forward small angle scatter having a small scattering angle impinges on the first lens element 15b to be collected thereby, and is then received by the second detector 17. Forward large angle scatter having a large scattering angle impinges on the second lens element 15c in the outermost periphery to be collected thereby, and is then received by the third detector 18 which is remotest from the composite lens.

Abstract: The present invention relates to a process for producing a conjugate of a biologically active peptide or protein having at least one glutamine residue with a high-molecular weight substance containing an amino group. The present invention also relates to a composite of this conjugate with a nucleic acid adsorbed thereto for transferring nucleic acids to mammalian cells.

Abstract: A process for modifying a physiologically active peptide or a physiologically active protein which comprises reacting a physiologically active peptide or a physiologically active protein having at least a glutamine residue with a substance having an amino donor in the presence of a transglutaminase originating in a microorganism to thereby form an acid amide bond at the .gamma.-position acid amide group of the glutamine residue with the amino group of the amino donor; and the product of modification obtained thereby.

Abstract: A power window motor drive apparatus, which, in the event of data error of the external command data, from the driver's seat limits the generation of drive signals for the power window motor that are based on the internal command data internally generated by the operation of the window switch and on the external command data received from outside through the communications line. An external command data reference inhibit means is provided to inhibit only the generation of the drive signals based on the external command data.

Abstract: There are disclosed (i) a purification process for obtaining a human BCDF having the intramolecular disulfide linkage and the stereostructure of natural type human BCDF which comprises subjecting to an oxidation reaction and a refolding treatment a reduced type human BCDF obtained by culturing a microorganism having a human BCDF gene integrated therein and solubilized with guanidine hydrochloride, characterized in that after the oxidation reaction, a gel filtration chromatographic treatment is conducted under the conditions of the guanidine hydrochloride concentration adjusted to 4-7M; (ii) a purification process for obtaining a natural type human BCDF monomer by removing the organic solvent from an organic solvent-containing solution of human BCDF, characterized in that the solution is passed through a gel filtration chromatographic column equilibrated with an organic solvent, followed by eluting according to a stepwise or linear gradient program; and (iii) a human BCDF purification process comprising an ion

Abstract: A purified human B-cell differentiation factor (BCDF) which does not have a natural signal peptide attached to the N-terminal thereof, DNA encoding the BCDF, transformed cells containing such DNA, a process for producing and obtaining the BCDF, and compositions containing the BCDF are disclosed.

Abstract: A microbial pesticide containing a living Erwinia carotovora subsp. carotovora, particularly, the Erwinia cartovora subsp. carotovora CGE234M403 strain, from which the pathogenicity of soft rot is deleted by mutagenesis and which is immobilized by mixing with a saccharide such as saccharose, glucose, fructose or sorbitol or beef extract and drying or freeze-drying the mixture under reduced pressure, as an active ingredient is applied to soil or plants, which are liable to suffer from soft rot, bacterial seedling blight of rice and black rot, in the form of a suspension, granules or powder to control the diseases.

Abstract: A purified human B-cell differentiation factor (BCDF) which does not have a natural signal peptide attached to the N-terminal thereof, DNA encoding the BCDF, transformed cells containing such DNA, a process for producing and obtaining the BCDF, compositions containing the BCDF and various therapeutic uses are disclosed.

Abstract: A highly retrovirus-producing DNA construct, which comprises a gene encoding retrovirus which is incorporated into a vector for gene amplification.

Abstract: A composition and a method for supporting bone marrow transplantation are disclosed. The composition comprises a therapeutically acceptable amount of human B cell differentiation factor, or its biological equivalent, optionally in combination with an auxiliary agent selected from IL-1, IL-3, IL-4, IL-5, G-CSF, GM-CSF, and M-CSF. The composition also promotes the proliferation of hematopoietic cells in vitro.